GSK taps Omnicom's PHD as media agency of record

Share this article:

GlaxoSmithKline tapped Omnicom's PHD as media agency of record on all of its healthcare products, ousting incumbent WPP's MediaCom.

The Omnicom media agency will handle media planning and buying for OTC and prescription products with exception to Boniva, which GSK co-promotes with Genentech.

“PHD offered the most balance of strategic planning excellence and executional creativity and buying leverage to deliver efficiency and quality, and they're an innovator in the digital media space,” said a GSK spokesperson.

Advertising Age reported that Havas' MPG and Publicis' Starcom were also-rans in the review as well.

Separately, the company has just completed round two of an agency review for all of its US prescription drug advertising. The shortlist, such as it is, is comprised of 20 agencies, and a decision is expected on that early in the new year. Interpublic Group healthcare shops currently handle most of that business. 

Meanwhile, Pfizer announced it was retaining Aegis Group's Carat for media planning and buying following a review. "We are pleased to continue our nearly 11-year relationship with Carat as its agency of record for direct-to-consumer media planning and buying for the pharmaceutical business across all communications channels, and for TV and print buying for the over-the-counter consumer healthcare business in the US," said Ray Kerins, VP external affairs and worldwide communications at Pfizer. "This follows a routine review to ensure Pfizer retains the services that best fits the needs of its business."

Share this article:

Email Newsletters

More in News

Sales of Biogen MS pill pick up overseas

Sales of Biogen MS pill pick up overseas

Biogen Idec is seeing strong sales for blockbuster MS drug Tecfidera, especially overseas where it's beginning to catch fire this summer.

GSK second-quarter sales disappoint

GSK second-quarter sales disappoint

Executives urge analysts to focus on the company's long-term potential.

House bill would speed approval once EU OKs same product

House bill would speed approval once EU OKs ...

The Speeding Access to Already Approved Pharmaceuticals Act of 2014 would require FDA to expedite the review of pharmaceuticals that are already approved by the European Union